Cairn Surgical

CairnSurgical is a private, clinical-stage medical device company targeting a critical unmet need in oncology surgery: the high rate of positive tumor margins in breast-conserving surgery (BCS). Its core technology platform translates patient-specific supine MRI scans into 3D-printed physical guides (the Breast Cancer Locator) that fit the unique contour of a patient's breast, aiming to provide surgeons with precise intraoperative guidance on tumor location, size, and margins. The company is currently conducting a pivotal U.S. clinical trial to demonstrate the BCL's superiority over the standard-of-care wire localization method, with the goal of improving surgical outcomes, reducing re-operation rates, and lowering overall healthcare costs.

Patient-specific surgical guidance platform that uses supine MRI data to create 3D-printed, custom-fit surgical guides for tumor excision.

CairnSurgical competes with the entrenched standard of care, wire localization, as well as other technologies like radioactive seeds, magnetic tags, and intraoperative ultrasound. It also faces potential competition from broader intraoperative margin assessment tools (e.g., frozen section, imprint cytology, spectroscopic probes) and other companies developing 3D surgical guidance platforms.